Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy

Biology Direct

Volumn 6, Issue , 2011, Pages

  Sedaghat, Ahmad R ^a   Wilke, Claus O ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Antiretroviral therapy; Haart; Hiv; Ic50; Pharmacodynamics; Viral dynamics; Viral life cycle

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

ANTIRETROVIRUS AGENT;

ARTICLE; CD4+ T LYMPHOCYTE; DRUG EFFECT; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; KINETICS; MACROPHAGE; PATHOGENICITY; PHYSIOLOGY; THEORETICAL MODEL; VIREMIA; VIROLOGY; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; DRUG SYNERGISM; HIV; HIV INFECTIONS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MACROPHAGES; MODELS, THEORETICAL; VIREMIA; VIRUS REPLICATION;

EID: 80052554881     PISSN: None     EISSN: 17456150     Source Type: Journal    
DOI: 10.1186/1745-6150-6-42     Document Type: Article

References (33)

1. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel. JAMA 2008, 300(5):555-570. 10.1001/jama.300.5.555, 18677028.
2. Dunning J, Nelson M. Novel strategies to treat antiretroviral-naive HIV-infected patients. J Antimicrob Chemother 2009, 64(4):674-679. 10.1093/jac/dkp239, 19643777.
3. McKinnon JE, Mellors JW, Swindells S. Simplification strategies to reduce antiretroviral drug exposure: Progress and prospects. Antivir Ther 2009, 14(1):1-12. 2716749, 19320232.
4. Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, et al. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004, 78(4):1718-1729. 10.1128/JVI.78.4.1718-1729.2004, 369469, 14747537.
5. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008, 14(7):762-766. 10.1038/nm1777, 2743464, 18552857.
6. Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, et al. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother 2009,
7. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 2008, 105(12):4832-4837. 10.1073/pnas.0711372105, 2290747, 18362342.
8. Sedaghat AR, Siliciano RF, Wilke CO. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther 2009, 14(2):263-271. 2980788, 19430101.
9. Chou TC. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharm 1974, 10:235-247.
10. Atkins GL, Nimmo IA. Current trends in the estimation of michaelis-menten parameters. Anal Biochem 1980, 104(1):1-9. 10.1016/0003-2697(80)90268-7, 6992643.
11. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, et al. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 2001, 194(12):1731-1741. 10.1084/jem.194.12.1731, 2193579, 11748275.
12. Rouzine IM, Sergeev RA, Glushtsov AI. Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus. Proc Natl Acad Sci USA 2006, 103(3):666-671. 10.1073/pnas.0510016103, 1334670, 16407101.
13. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271(5255):1582-1586. 10.1126/science.271.5255.1582, 8599114.
14. Mittler JE, Markowitz M, Ho DD, Perelson AS. Improved estimates for HIV-1 clearance rate and intracellular delay. AIDS 1999, 13(11):1415-1417. 10.1097/00002030-199907300-00023, 10449298.
15. Abbotts J, Jaju M, Wilson SH. Thermodynamics of A:G mismatch poly(dG) synthesis by human immunodeficiency virus 1 reverse transcriptase. J Biol Chem 1991, 266(6):3937-3943.
16. Reddy B, Yin J. Quantitative intracellular kinetics of HIV type 1. AIDS Res Hum Retroviruses 1999, 15(3):273-283. 10.1089/088922299311457, 10052758.
17. Wang J, Kondo N, Long Y, Iwamoto A, Matsuda Z. Monitoring of HIV-1 envelope-mediated membrane fusion using modified split green fluorescent proteins. J Virol Methods 2009, 161(2):216-222. 10.1016/j.jviromet.2009.06.017, 19559731.
18. Stebbing J, Gazzard B, Douek DC. Where does HIV live?. N Engl J Med 2004, 350(18):1872-1880. 10.1056/NEJMra032395, 15115833.
19. Stevenson M. HIV-1 pathogenesis. Nat Med 2003, 9(7):853-860. 10.1038/nm0703-853, 12835705.
20. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003, 21:265-304. 10.1146/annurev.immunol.21.120601.141053, 12524385.
21. Spivak A, Rabi A, McMahon M, Siliciano RF. Understanding decay of viremia in patients on raltegravir. Conference on Retroviruses and Opportunistic Infections (552) 2009,
22. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, et al. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 2002, 76(17):8518-8531. 10.1128/JVI.76.17.8518-8513.2002, 136977, 12163571.
23. Carroll SS, Stahlhut M, Geib J, Olsen DB. Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. differences in the rates of inhibitor binding and in synergistic inhibition with nucleoside analogs. J Biol Chem 1994, 269(51):32351-32357.
24. Markgren PO, Schaal W, Hamalainen M, Karlen A, Hallberg A, et al. Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. J Med Chem 2002, 45(25):5430-5439. 10.1021/jm0208370, 12459011.
25. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44(4):920-928. 10.1128/AAC.44.4.920-928.2000, 89793, 10722492.
26. Ferguson NM, Fraser C, Anderson RM. Viral dynamics and anti-viral pharmacodynamics: Rethinking in vitro measures of drug potency. Trends Pharmacol Sci 2001, 22(2):97-100. 10.1016/S0165-6147(00)01615-1, 11166854.
27. McMahon MA, Shen L, Siliciano RF. New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr Opin Infect Dis 2009, 22(6):574-582. 10.1097/QCO.0b013e328332c54d, 19841584.
28. Gao WY, Zhou BS, Johns DG, Mitsuya H, Yen Y. Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine. Biochem Pharmacol 1998, 56(1):105-112. 10.1016/S0006-2952(98)00127-0, 9698094.
29. Fumero E, Podzamczer D. New patterns of HIV-1 resistance during HAART. Clin Microbiol Infect 2003, 9(11):1077-1084. 10.1046/j.1469-0691.2003.00730.x, 14616723.
30. Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol 2009, 83(10):4884-4894. 10.1128/JVI.02659-08, 2682084, 19279107.
31. Perez-Olmeda M, Garcia-Perez J, Mateos E, Spijkers S, Ayerbe MC, et al. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. J Med Virol 2009, 81(2):211-216. 10.1002/jmv.21377, 19107982.
32. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000, 25(2):99-102. 10.1097/00126334-200010010-00001, 11103038.
33. Snyder S, D'Argenio DZ, Weislow O, Bilello JA, Drusano GL. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother 2000, 44(4):1051-1058. 10.1128/AAC.44.4.1051-1058.2000, 89812, 10722511.